These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 26031842)

  • 1. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.
    Zuccari G; Milelli A; Pastorino F; Loi M; Petretto A; Parise A; Marchetti C; Minarini A; Cilli M; Emionite L; Di Paolo D; Brignole C; Piaggio F; Perri P; Tumiatti V; Pistoia V; Pagnan G; Ponzoni M
    J Control Release; 2015 Aug; 211():44-52. PubMed ID: 26031842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma.
    Di Paolo D; Pastorino F; Zuccari G; Caffa I; Loi M; Marimpietri D; Brignole C; Perri P; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M; Pagnan G
    J Control Release; 2013 Sep; 170(3):445-51. PubMed ID: 23792118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
    Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
    Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib.
    Loi M; Becherini P; Emionite L; Giacomini A; Cossu I; Destefanis E; Brignole C; Di Paolo D; Piaggio F; Perri P; Cilli M; Pastorino F; Ponzoni M
    J Control Release; 2014 Oct; 192():157-66. PubMed ID: 25041999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
    Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
    Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.
    Pastorino F; Brignole C; Di Paolo D; Nico B; Pezzolo A; Marimpietri D; Pagnan G; Piccardi F; Cilli M; Longhi R; Ribatti D; Corti A; Allen TM; Ponzoni M
    Cancer Res; 2006 Oct; 66(20):10073-82. PubMed ID: 17047071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
    Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F
    J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo.
    Shi C; Cao H; He W; Gao F; Liu Y; Yin L
    Biomed Pharmacother; 2015 Jul; 73():48-57. PubMed ID: 26211582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
    Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
    Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposome-mediated therapy of neuroblastoma.
    Di Paolo D; Loi M; Pastorino F; Brignole C; Marimpietri D; Becherini P; Caffa I; Zorzoli A; Longhi R; Gagliani C; Tacchetti C; Corti A; Allen TM; Ponzoni M; Pagnan G
    Methods Enzymol; 2009; 465():225-49. PubMed ID: 19913170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation, characterization and in vitro evaluation of sterically stabilized liposome containing a naphthalenediimide derivative as anticancer agent.
    Parise A; Milelli A; Tumiatti V; Minarini A; Neviani P; Zuccari G
    Drug Deliv; 2015; 22(5):590-7. PubMed ID: 24286206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics.
    Mahmoudian M; Valizadeh H; Löbenberg R; Zakeri-Milani P
    J Microencapsul; 2021 May; 38(3):192-202. PubMed ID: 33530812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
    Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
    J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycine-Poly-L-Lactic Acid Copolymeric Nanoparticles for the Efficient Delivery of Bortezomib.
    Rajoria S; Rani S; Chaudhari D; Jain S; Gupta U
    Pharm Res; 2019 Sep; 36(11):160. PubMed ID: 31520196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
    Li X; Ding L; Xu Y; Wang Y; Ping Q
    Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.
    Pastorino F; Brignole C; Marimpietri D; Sapra P; Moase EH; Allen TM; Ponzoni M
    Cancer Res; 2003 Jan; 63(1):86-92. PubMed ID: 12517782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.
    Pastorino F; Di Paolo D; Piccardi F; Nico B; Ribatti D; Daga A; Baio G; Neumaier CE; Brignole C; Loi M; Marimpietri D; Pagnan G; Cilli M; Lepekhin EA; Garde SV; Longhi R; Corti A; Allen TM; Wu JJ; Ponzoni M
    Clin Cancer Res; 2008 Nov; 14(22):7320-9. PubMed ID: 19010847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion.
    Cossu I; Bottoni G; Loi M; Emionite L; Bartolini A; Di Paolo D; Brignole C; Piaggio F; Perri P; Sacchi A; Curnis F; Gagliani MC; Bruno S; Marini C; Gori A; Longhi R; Murgia D; Sementa AR; Cilli M; Tacchetti C; Corti A; Sambuceti G; Marchiò S; Ponzoni M; Pastorino F
    Biomaterials; 2015 Nov; 68():89-99. PubMed ID: 26276694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma.
    Hamner JB; Dickson PV; Sims TL; Zhou J; Spence Y; Ng CY; Davidoff AM
    Surgery; 2007 Aug; 142(2):185-91. PubMed ID: 17689684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HO-1 up-regulation: a key point in high-risk neuroblastoma resistance to bortezomib.
    Furfaro AL; Piras S; Passalacqua M; Domenicotti C; Parodi A; Fenoglio D; Pronzato MA; Marinari UM; Moretta L; Traverso N; Nitti M
    Biochim Biophys Acta; 2014 Apr; 1842(4):613-22. PubMed ID: 24380881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.